(Q34657289)

3 August 2017

1 reference

title

Fludarabine: a review of its use in non-Hodgkin's lymphoma (English)

1 reference

3 August 2017

2

Caroline M Perry

1 reference

3 August 2017

Vanessa R Anderson

1

1 reference

3 August 2017

1 January 2007

1 reference

3 August 2017

1 reference

3 August 2017

67

1 reference

3 August 2017

11

1 reference

3 August 2017

1633-1655

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767110-00008

3 August 2017

0 references

cites work

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma

1 reference

12 December 2020

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

1 reference

12 December 2020

The bioavailability of oral fludarabine phosphate is unaffected by food

1 reference

12 December 2020

Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

1 reference

12 December 2020

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

12 December 2020

Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study

1 reference

12 December 2020

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

1 reference

12 December 2020

Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine

1 reference

12 December 2020

1 reference

12 December 2020

Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.

1 reference

12 December 2020

Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients

1 reference

12 December 2020

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

12 December 2020

Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma

1 reference

12 December 2020

A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.

1 reference

12 December 2020

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

1 reference

12 December 2020

Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway

1 reference

12 December 2020

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

1 reference

12 December 2020

Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment

1 reference

12 December 2020

A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma

1 reference

12 December 2020

Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

1 reference

12 December 2020

Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group

1 reference

12 December 2020

Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen

1 reference

12 December 2020

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

12 December 2020

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

12 December 2020

Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma

1 reference

12 December 2020

Lymphoma: diagnosis, staging, natural history, and treatment strategies

1 reference

12 December 2020

Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the

1 reference

12 December 2020

Cellular and clinical pharmacology of fludarabine

1 reference

12 December 2020

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

1 reference

12 December 2020

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

1 reference

12 December 2020

Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

1 reference

12 December 2020

Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

12 December 2020

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

1 reference

12 December 2020

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology

1 reference

12 December 2020

Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501

1 reference

12 December 2020

Cancer statistics, 2007

1 reference

12 December 2020

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies

1 reference

12 December 2020

10.2165/00003495-200767110-00008

Identifiers

DOI

1 reference

PubMed ID

17661532

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

17661532